Osteoarthritis Market 2023 Top Players | Novartis AG, ABIOGEN PHARMA S.p.A, TissueGene Inc, Ampio Pharmaceuticals Inc and More

Osteoarthritis is a type of arthritis that occurs when flexible tissue at the ends of bones wears down. Increasing age is the major factor for the cause of the disease. Market Research Future, a firm which specializes in market reports related to the healthcare sector among others, recently forecasted in its report on Global Osteoarthritis Market Research Report- Forecast to 2023 that the market will demonstrate a steady CAGR while achieving million dollar growth readily in the forecast period.

The Global Osteoarthritis Market is expected to grow at an approximate CAGR of 6.8% during the forecast period 2018-2023.

Osteoarthritis is the most common form of arthritis which generally affects the hands, knee, hip and spines. It can causes pain, swelling, and reduced motion in the joints. Geriatric population and over-weighted individuals are at higher risks of osteoarthritis. Factors like growing geriatric population, rising prevalence of the osteoarthritis and increasing per capita healthcare expenditure will drive the market growth during the forecast period. In 2015, according to the National Institutes of Health, the American geriatric population is expected to nearly double from 48 million in 2015 to 88 million by 2050. Moreover, in 2015, according to the Centres for Disease Control and Prevention, in the U.S. the total healthcare expenditure accounted for 17.8% of the total gross domestic product (GDP), which accounted for USD 3.2 trillion. However, low per capita income in the developing countries and side effects of the treatment procedures will restrain the market growth during the forecast period

Owing to the increasing number of the people suffering from osteoarthritis many companies are involved in the manufacturing and introduction of the better and effective treatment and diagnostic options. A number of diagnostic treatment such as imaging (X-rays, magnetic resonance imaging (MRI), and bone scan), joint fluid analysis and others are available. However these are not that effective thus, many private and government organizations are providing support to the manufacturer for the development of the new and advanced devices.

Get a Sample Copy of This Report @ https://www.marketresearchfuture.com/sample_request/1609 .

Competitive Analysis:

A number of industries are working in the development and production of osteoarthritis products. It is found out that the market players have adopted the organic strategy of development of better and cost-effective products, and acquisition. The companies are aiming to capture a considerable share of the market segment as early as possible, due to continuously increasing competition. In order to gain the customer attention the companies have launched innovate products.

The key players profiled in osteoarthritis are Abbott. (U.S.), Novartis AG (Europe), Pfizer Inc. (U.S.), Eli Lilly and Company. (U.S.), ABIOGEN PHARMA S.p.A (Europe), Merck Sharp & Dohme Corp. (U.S.), TissueGene Inc. (U.S.), Ampio Pharmaceuticals Inc. (U.S.), Regeneron (U.S.), and others.

Latest Industry Updates:

Being a competitive market, a number of different manufacturer are focusing on the product launch, and acquisition for the market development. Some of the latest development in the market are-

May 2017 Ablynx, a biopharmaceutical company headquartered in Belgium, announced the completion of a preclinical package for a novel nanobody, ALX-1141 for the treatment of the osteoarthritis. Merck will now be responsible for further clinical development of the molecule.

Jul 2017, Kolon Pharmaceutical got the approval for the World's first cell and gene therapy for knee osteoarthritis in Korea.

Aug 2016, Bioventus, a global leader in orthobiologic solutions launched GELSYN-3, a three-injection hyaluronic acid (HA) product for pain relief associated with osteoarthritis (OA) of the knee.

Segmentation:

The global osteoarthritis market is segmented on the basis of type, diagnosis, treatment, and end users.

On the basis of type, the market is segmented into hip osteoarthritis, wrist osteoarthritis, spinal osteoarthritis, and others.

On the basis of diagnosis, the market is segmented into imaging, joint fluid analysis, and others. The imaging segment, is sub segmented into X-rays, magnetic resonance imaging (MRI), and others.

Get Attractive Discount @ https://www.marketresearchfuture.com/check-discount/1609 .

On the basis of treatment, the market is segmented into medication, surgery, therapy, and others. The medication segmented is sub segmented into analgesics and non-steroidal anti-inflammatory drugs, and others. The analgesics sub segment, by medication, is further segmented into acetaminophen, duloxetine, and others. The non-steroidal anti-inflammatory drugs sub segment, by medication, is further segmented into aspirin, ibuprofen, naproxen sodium and naproxen, and others.

On the basis of end users, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.

…Continued

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:
Market Research Future
+1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.